Incidence of scleritis requiring surgical repair from subconjunctival triamcinolone acetonide injections in patients with scleritis in TriNetX.
No scleritis patients needed surgical repair after triamcinolone eye injections
Incidence of scleritis requiring surgical repair from subconjunctival triamcinolone acetonide injections in patients with scleritis in TriNetX.
To estimate the yearly and 15-year cumulative incidence of scleritis requiring surgical repair in patients with a prior diagnosis of scleritis who received a subconjunctival or subTenon triamcinolone acetonide injection (subTenon triamcinolone acetonide injection).
To estimate the yearly and 15-year cumulative incidence of scleritis requiring surgical repair in patients with a prior diagnosis of scleritis who received a subconjunctival or subTenon triamcinolone acetonide injection (subTenon triamcinolone acetonide injection).
A retrospective cohort study was conducted using the TriNetX US Collaborative Network.
Out of 113,510,724 patients on the TriNetX database, 36,249 had a diagnosis of scleritis.
Of those with a history of scleritis, 176 had a subconjunctival or subTenon triamcinolone injection (subTenon triamcinolone acetonide injection).
The subjects were primarily female (112, 63.64%) with a mean age of 61 years (range 14-90, SD 16).
Surgical intervention requiring a patch graft was not observed post-injection among patients with prior scleritis who received a subTenon triamcinolone acetonide injection.
Further studies with larger cohorts are necessary to accurately represent the risk profile of subTenon triamcinolone acetonide injection in the greater population.